MarketCap
Facebook
X
Telegram
Aptose Biosciences Interest Expense | APTO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Quarterly Interest Expense Aptose Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19 K | -212 K | -110 K | -84 K | - | 12 K | 93 K | 121 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 121 K | -212 K | -28.4 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ASLAN Pharmaceuticals Limited
ASLN
|
442 K | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Revolution Medicines
RVMD
|
71 K | $ 207.32 | 0.24 % | $ 39.4 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
1.26 M | $ 101.8 | 0.08 % | $ 6.62 B | USA |
 |
Rezolute
RZLT
|
375 K | $ 4.4 | 0.88 % | $ 334 M | USA |
 |
Sana Biotechnology
SANA
|
2.3 M | $ 3.45 | 0.77 % | $ 874 M | USA |
 |
Seer
SEER
|
22 K | $ 1.95 | 0.26 % | $ 108 M | USA |
 |
Precigen
PGEN
|
43 K | $ 6.87 | 0.14 % | $ 2.15 B | USA |
 |
SIGA Technologies
SIGA
|
3.02 M | $ 3.2 | 1.86 % | $ 229 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-1.28 M | $ 19.94 | 0.05 % | $ 1.73 B | USA |
 |
Soligenix
SNGX
|
-11.7 K | $ 0.38 | 1.18 % | $ 1.97 M | USA |
 |
Spruce Biosciences
SPRB
|
90 K | $ 59.09 | 2.0 % | $ 45.3 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-38.1 M | $ 20.94 | 0.04 % | $ 2.1 B | USA |
 |
Stoke Therapeutics
STOK
|
9 K | $ 30.05 | 0.81 % | $ 1.78 B | USA |
 |
Sutro Biopharma
STRO
|
1.62 M | $ 19.1 | 0.34 % | $ 162 M | USA |
 |
Shattuck Labs
STTK
|
-4 K | $ 6.5 | 0.29 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
13.3 M | $ 42.43 | 0.23 % | $ 2.4 B | USA |
 |
Savara
SVRA
|
4.71 M | $ 5.53 | 2.98 % | $ 1.23 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
477 K | $ 2.24 | 0.45 % | $ 1.52 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
137 B | $ 18.32 | 1.49 % | $ 28.9 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
-5.8 M | $ 72.31 | 0.01 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
23 K | $ 1.98 | 2.06 % | $ 77.7 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
916 M | $ 36.76 | 1.21 % | $ 42.1 B |  Israel |
 |
TG Therapeutics
TGTX
|
10.8 M | $ 55.74 | 0.58 % | $ 8.04 B | USA |
 |
Trevi Therapeutics
TRVI
|
-31 K | $ 16.82 | 1.17 % | $ 2.27 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-291 K | $ 5.48 | 0.54 % | $ 1.75 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-284 K | $ 43.82 | 0.02 % | $ 2.11 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
48.9 M | $ 497.97 | 2.12 % | $ 22.1 B | USA |
 |
Spero Therapeutics
SPRO
|
7 K | $ 1.19 | 0.41 % | $ 66.7 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
-301 K | $ 57.42 | 3.78 % | $ 6.59 B | USA |
 |
Jounce Therapeutics
JNCE
|
1.46 M | - | - | $ 98.4 M | USA |
 |
NextCure
NXTC
|
1.77 M | $ 8.42 | 7.67 % | $ 23.9 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-3 K | $ 5.26 | 0.75 % | $ 56 M | USA |
 |
Viridian Therapeutics
VRDN
|
500 K | $ 23.17 | 1.09 % | $ 2.36 B | USA |
 |
Zosano Pharma Corporation
ZSAN
|
189 K | - | 7.23 % | $ 2.72 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
-7.7 M | $ 528.9 | 0.22 % | $ 135 B | USA |
 |
Verastem
VSTM
|
1.14 M | $ 8.08 | 0.55 % | $ 560 M | USA |
 |
vTv Therapeutics
VTVT
|
13 K | $ 32.79 | 0.03 % | $ 130 M | USA |
 |
Voyager Therapeutics
VYGR
|
1.65 M | $ 3.4 | 3.85 % | $ 200 M | USA |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
527 K | $ 4.91 | 1.03 % | $ 828 M | Singapore |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-3.3 M | $ 13.16 | 0.15 % | $ 112 M | USA |
 |
Xenetic Biosciences
XBIO
|
5.72 K | $ 4.28 | 0.86 % | $ 7.28 M | USA |
|
XBiotech
XBIT
|
1.46 M | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Exicure
XCUR
|
-275 K | $ 1.41 | 12.8 % | $ 8.88 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
484 K | $ 59.55 | 0.18 % | $ 4.72 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
-24.3 M | $ 8.48 | 0.12 % | $ 1.36 B | USA |